Abstract: Aspects of the disclosure provide for automatically generating patches for security violations. For example, a plurality of inputs may be generated for code. The code may be executed using the plurality of inputs to obtain execution states at a plurality of code locations. The execution states may include at least one security violation for at least some of the plurality of inputs. Using the execution states, one or more patch conditions causing the at least one security violation may be determined. Using the execution states, one or more corresponding patch locations may be determined based on a code location of the plurality of code locations where the at least one security violation each of the one or more patch conditions occurred. At least one candidate patch for the at least one security violation may be automatically generated. The at least one candidate patch may include one of the patch conditions and one of the corresponding patch locations.

Abstract: A system and method are provided for testing the performance of applications. By way of example only, the method may include training a neural network with documents containing text elements that are arranged in accordance with a defined format and using the neural network to determine the predictability of the value of individual text elements within a test document. When the neural network indicates that the value of a text element is unlikely, the value may be modified and the modified document may be used to test an application that processes documents in accordance with the defined format.

Abstract: A system and method are provided for testing the performance of applications. By way of example only, the method may include training a neural network with documents containing text elements that are arranged in accordance with a defined format and using the neural network to determine the predictability of the value of individual text elements within a test document. When the neural network indicates that the value of a text element is unlikely, the value may be modified and the modified document may be used to test an application that processes documents in accordance with the defined format.

Abstract: A system and method are provided for testing the performance of applications. By way of example only, the method may include training a neural network with documents containing text elements that are arranged in accordance with a defined format and using the neural network to determine the predictability of the value of individual text elements within a test document. When the neural network indicates that the value of a text element is unlikely, the value may be modified and the modified document may be used to test an application that processes documents in accordance with the defined format.

Abstract: A system and method are provided for testing the performance of applications. By way of example only, the method may include training a neural network with documents containing text elements that are arranged in accordance with a defined format and using the neural network to determine the predictability of the value of individual text elements within a test document. When the neural network indicates that the value of a text element is unlikely, the value may be modified and the modified document may be used to test an application that processes documents in accordance with the defined format.

Abstract: The invention relates to novel diphenylpropylamine derivatives of the general formula (I). ##STR1## R.sup.1 stands for hydrogen or a methyl group; R.sup.2 stands for hydrogen, a methyl or n-decyl group;Z means a phenyl group substituted by R.sup.3, R.sup.4 and R.sup.5, whereinR.sup.3 means hydrogen, fluorine, chlorine or bromine, or a nitro, C.sub.1-12 alkyl, C.sub.1-4 alkoxy, phenoxy or benzyloxy group;R.sup.4 and R.sup.5 represent hydrogen, chlorine or a hydroxy, alkoxy, benzyloxy, acetamino or carboxy group; orR.sup.4 and R.sup.5 together form a methylendioxy group;orZ may stand for a 4-methoxynaphtyl or 4-ethoxy-naphthyl group; andR.sup.6 stands for hydrogen or fluorine, with the proviso that each of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 cannot simultaneously stand for hydrogen, as well as their physiologically acceptable acid addition salts.The invention also relates to a process for the preparation of these compounds and to the pharmaceutical compositions containing these compounds.

Abstract: The invention relates to new 7-oxo-PGI.sub.2 -ephedrine salt analogues of the Formula I ##STR1## wherein A stands for --(CH.sub.2).sub.2 --, cis or trans --CH.dbd.CH-- or --C.tbd.C--;R.sup.1 is lower alkyl or hydrogen;B represents a chemical bond, --CH.sub.2 -- or --CR.sup.2 R.sup.3 ;R.sup.2 stands for lower alkyl or hydrogen;R.sup.3 represents lower alkyl or hydrogen;X is a chemical bond, --O-- or --CH.sub.2 --;R.sup.4 stands for C.sub.1-6 alkyl, C.sub.4-7 cycloalkyl, C.sub.1-6 fluoroalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, phenyl, substituted phenyl or heteroaryl.The salts of the Formula I show the same pharmacological profile as the sodium salt of PGI.sub.2, they inhibit blood aggregation and the secretion of gastric acid, are useful in the prevention of anginal attacks.

Abstract: The invention relates to new cyclic imines of the general formula (I), ##STR1## wherein A represents carbonyl or hydroxymethylene,B is oxygen or imino,R stands for hydrogen or lower alkyl,X.sub.1 and X.sub.2 may be the same or different and represent hydrogen, halogen, lower alkyl or alkoxy, amino or nitro,n is 6 or 7, andm is 0 or 1,and pharmaceutically acceptable acid addition salts and quaternary salts thereof. The invention relates further to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds as the active ingredient and to a process for the preparation of said pharmaceutical compositions.The cyclic imine derivatives of the invention possess valuable antiarrhythmic properties and can be used to advantage in the treatment of cardiovascular diseases.

Abstract: The invention concerns new compounds of the formula (I) ##STR1## wherein R.sup.1 is hydrogen, phenyl or phenyl substituted with at least one alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro;R.sup.2 is alkyl having 1 to 4 carbon atoms, cycloalkyl having 5 to 7 carbon atoms, phenyl, or phenyl substituted with at least one alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro;R.sup.3 is alkoxy having 1 to 4 carbon atoms or hydrogen,R.sup.4 is hydrogen, alkyl having 1 to 4 carbon atoms unsubstituted or substituted with alkoxy having 1 to 4 carbon atoms, benzyloxy or cyano, phenyl, or phenyl substituted with at least one alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro, or phenyl-(C.sub.1-4 alkyl)-alkyl, in which the phenyl moiety may bear an alkoxy substituent having 1 to 4 carbon atoms or a halogen;m and n are each 0, 1 or 2 or a pharmaceutically acceptable acid addition or quaternary salt thereof.

Abstract: A compound of the formula ##STR1## wherein R is hydroxy, alkoxy or acyloxyQ is sulfur or a .dbd.N--R.sup.1 group, wherein R.sup.1 ishydrogen, C.sub.1-5 alkyl or aralkyl or C.sub.2-4 acyl, or a pharmaceutically acceptable acid addition salt thereof.

Abstract: The invention relates to new thiazoloisoquinolines of the formula (I), or pharmaceutically acceptable salts thereof, ##STR1## wherein R.sup.1 is hydrogen, hydroxy, alkoxy or aralkoxy,R.sup.2 is hydrogen, hydroxy, alkoxy or aralkoxy,R.sup.3 is hydrogen, cyano, alkyl, aryl, nitro, carboxy, carboalkoxy or carboxamido, andY is oxygen, sulfur, or a group of the formula .dbd.N--R.sup.4, wherein R.sup.4 stands for hydrogen, alkyl, aryl, acyl, alkyl-sulfonyl or arysulfonyl.These new compounds can be used in practice as heart medicines or respiratory analeptics.

Abstract: 1-Cyano-2-imino-2H,4H-5,6-dihydro-8,9-dimethoxy-1,2-thiazolo(3,2a)isoquinol ine or 2-imino-2H,4H-5,6-dihydro-8,9-dimethoxy-1,2-thiazolo(3,2a)isoquinoline or a pharmaceutically acceptable salt thereof. These compounds are effective as heart medicines and respiratory analeptics.

Abstract: A basic ester having the formula ##STR1## wherein Ac is benzoyl substituted by at least two substituents selected from the group which consist of halogen atoms, lower alkyl, lower alkoxy, hydroxy, nitro and sulfamoyl, and A B are hydrogen or lower alkyl or are cycloalkyl together. The compounds are therapeutic for cardic conditions.

Abstract: The invention relates to new thiazoloisoquinolines of the general formula (I), or salts thereof, ##SPC1##WhereinA stands for a group of the formula ##EQU1## R.sup.1 stands for hydrogen, hydroxy, alkoxy or aralkoxy, R.sup.2 stands for hydrogen, hydroxy, alkoxy or aralkoxy,R.sup.3 stands for hydrogen, alkyl, aryl, nitro, carboxy or a carboxy derivative, andY stands for oxygen, sulfur, or a group of the formula =N--R.sup.4, wherein R.sup.4 stands for hydrogen, alkyl, aryl, acyl, alkylsulfonyl or arylsulfonyl.These new compounds can be used in practice as heart medicines or respiratory analeptics.The new compounds according to the invention can be prepared as follows: an isoquinoline of the general formula (II) or a salt thereof ##SPC2##WhereinR.sup.5 stands for hydrogen, hydroxy, alkoxy or aralkoxy,R.sup.6 stands for hydrogen, hydroxy, alkoxy or aralkoxy,R.sup.